Institutional Investors Sentiment Indicator of Verastem Inc (NASDAQ:VSTM) Increases in 2019 Q1

Sentiment for Verastem Inc (NASDAQ:VSTM)

Verastem Inc (NASDAQ:VSTM) institutional sentiment increased to 1.35 in 2019 Q1. Its up 0.23, from 1.12 in 2018Q4. The ratio increased, as 46 funds opened new or increased positions, while 34 sold and decreased equity positions in Verastem Inc. The funds in our partner’s database now possess: 30.66 million shares, down from 41.14 million shares in 2018Q4. Also, the number of funds holding Verastem Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 23 Increased: 24 New Position: 22.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $111.55 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

The stock decreased 2.58% or $0.04 during the last trading session, reaching $1.51. About 854,806 shares traded. Verastem, Inc. (NASDAQ:VSTM) has declined 70.10% since July 14, 2018 and is downtrending. It has underperformed by 74.53% the S&P500.

Analysts await Verastem, Inc. (NASDAQ:VSTM) to report earnings on August, 14. They expect $-0.49 earnings per share, down 63.33 % or $0.19 from last year’s $-0.3 per share. After $-0.51 actual earnings per share reported by Verastem, Inc. for the previous quarter, Wall Street now forecasts -3.92 % EPS growth.

Deer Vii & Co. Ltd. holds 11.1% of its portfolio in Verastem, Inc. for 1.19 million shares. Bvf Inc Il owns 3.51 million shares or 1.16% of their US portfolio. Moreover, Cohen Capital Management Inc. has 0.18% invested in the company for 253,560 shares. The Massachusetts-based Howland Capital Management Llc has invested 0.05% in the stock. Alpine Woods Capital Investors Llc, a New York-based fund reported 50,040 shares.

Since January 1, 0001, it had 1 buy, and 0 selling transactions for $105,930 activity.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Ratings analysis reveals 100% of Verastem’s analysts are positive. Out of 4 Wall Street analysts rating Verastem, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5 while the high is $14. The stock’s average target of $8.75 is 479.47% above today’s ($1.51) share price. VSTM was included in 8 notes of analysts from March 13, 2019. H.C. Wainwright maintained it with “Buy” rating and $10 target in Thursday, March 14 report. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Buy” rating given on Wednesday, March 13 by Roth Capital. The stock of Verastem, Inc. (NASDAQ:VSTM) earned “Outperform” rating by Raymond James on Thursday, March 14.

More notable recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Benzinga.com which released: “Verastem Shares Response Rate From COPIKTRA Data – Benzinga” on June 21, 2019, also Seekingalpha.com with their article: “Verastem: Is The Short Thesis Short-Sighted? – Seeking Alpha” published on March 25, 2019, Seekingalpha.com published: “Don’t Give Up On Verastem – Seeking Alpha” on November 06, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) were released by: Seekingalpha.com and their article: “Verastem: Copiktra To Power Turnaround Prospect – Seeking Alpha” published on May 25, 2019 as well as Seekingalpha.com‘s news article titled: “Verstem up 6% premarket after Q3 report; duvelisib launch underway, $508K in sales in September – Seeking Alpha” with publication date: November 08, 2018.

Verastem, Inc. (NASDAQ:VSTM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.